Skip to search formSkip to main contentSkip to account menu

EGFR Inhibitor ABT-414

Known as: ABT-414 
An epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon intravenous infusion, ABT-414 inhibits the… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Background: The aim of this study was to prospectively analyse, for the first time worldwide by in vivo clinical confocal… 
2018
2018
Depatuxizumab mafodotin (depatux-m, ABT-414) is a tumor-selective antibody drug conjugate (ADC) comprised of the anti-EGFR… 
Highly Cited
2018
Highly Cited
2018
Background We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly… 
Highly Cited
2017
Highly Cited
2017
PurposePatients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene… 
2017
2017
2003Background: GBM is the most common malignant primary brain tumor in adults. Pts with rGBM have a poor prognosis. EGFR is… 
Highly Cited
2016
Highly Cited
2016
Targeting tumor-overexpressed EGFR with an antibody–drug conjugate (ADC) is an attractive therapeutic strategy; however, normal… 
Highly Cited
2016
Highly Cited
2016
Background The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety… 
2016
2016
2542Background: Recurrent GBM (rGBM) has dismal prognosis. Almost 50% GBM tumors harbor amplified (amp) EGFR. ABT-414 is a tumor… 
2015
2015
2016 Background: GBM remains almost universally fatal and new therapies are needed. The epidermal growth factor receptor (EGFR… 
2014
2014
2021 Background: Patients (pts) with recurrent GBM have few treatment options and a very poor prognosis. GBM tumors often exhibit…